The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

A worker at a tobacco company tests cigarettes coming off the line. A company within Alaris Royalty’s portfolio that provides tobacco toxicology testing services, ran into problems when the U.S. delayed enactment of new Federal Drug Agency tobacco regulation.
A worker at a tobacco company tests cigarettes coming off the line. A company within Alaris Royalty’s portfolio that provides tobacco toxicology testing services, ran into problems when the U.S. delayed enactment of new Federal Drug Agency tobacco regulation.
(PATRICK BERNATH/CNW)

Alaris Royalty on a mission to rebuild investor trust

All of a sudden there are questions about Alaris Royalty Corp.’s future, forcing management to do all it can to convince shareholders its recent hiccups are anomalies, not harbingers of doom.

Much like a private equity fund, Alaris buys stakes in a number of small companies. The majority of royalties earned from these investments are paid out to public shareholders in the form of dividends.